Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials

Original research

van Santen, Daniela K. et al

Release Date

2023

Geography

International

Language of Resource

English

Full Text Available

Yes

Open Access / OK to Reproduce

Yes

Peer Reviewed

Yes

Objective

We measured the pooled effect of needle and syringe program (NSP) and opioid agonist therapy (OAT) participation on HIV and HCV incidence in the Netherlands, Canada and Australia.

Findings/Key points

In the Netherlands, Canada and Australia, comprehensive needle and syringe program and opioid agonist therapy participation appears to substantially reduce HIV and hepatitis C acquisition compared with no or partial needle and syringe program/opioid agonist therapy participation

Design/methods

For each cohort, we emulated the design and statistical analysis of a target trial using observational data

doi.org

Keywords

Harm reduction

Substitution/OAT

Wrap-around services

About PWUD